Sotac Pharma.

When is the next results date for Sotac Pharma.?

No Upcoming Board Meetings

Has Sotac Pharma. declared dividend?

No Dividend History Available

Who are the peers of the Sotac Pharma.?

Sotac Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. In terms of management risk, growth, and capital structure, Sun Pharma, Cipla, and Dr Reddy's Labs perform excellently, while Lactose (India) and others show below-average results.

Peers: The peers of Sotac Pharma are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Lactose (India), Mangalam Drugs, Welcure Drugs, Vaishali Pharma, and Zenith.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Zenith, while Good management risk is found at Divi's Lab., Torrent Pharma, and the rest. Below Average management risk is noted for Lactose (India), Mangalam Drugs, Welcure Drugs, and Vaishali Pharma. Growth is Excellent at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Sotac Pharma., while Below Average growth is seen at Divi's Lab., Torrent Pharma, Lactose (India), Mangalam Drugs, Vaishali Pharma, and Zenith. Capital Structure is Excellent at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Good capital structure is found at Torrent Pharma, Average at Sotac Pharma., and Below Average at Lactose (India), Mangalam Drugs, Welcure Drugs, and Vaishali Pharma.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Lactose (India) has the lowest at -35.55%. Sotac Pharma.'s 1-year return is 0.00%, which is significantly lower than Divi's Lab. and higher than Lactose (India). Additionally, Lactose (India), Mangalam Drugs, and Vaishali Pharma have negative six-month returns.

What is the technical trend for Sotac Pharma.?

As of May 30, 2025, Sotac Pharma shows a mildly bullish trend overall, supported by the weekly MACD and moving averages, but caution is advised due to mixed signals from the weekly RSI and OBV.

As of 30 May 2025, the technical trend for Sotac Pharma has changed from sideways to mildly bullish. The weekly MACD indicates a bullish stance, while the daily moving averages also reflect a mildly bullish outlook. However, the weekly RSI is bearish, suggesting some weakness in momentum. The Bollinger Bands on a weekly basis are mildly bullish, but the monthly view is bearish. The KST is bullish on the weekly timeframe, while the OBV shows a mildly bearish trend. Overall, the current technical stance is mildly bullish, but the mixed signals, particularly from the RSI and OBV, indicate caution.

Who are in the management team of Sotac Pharma.?

As of March 2023, the management team of Sotac Pharma includes Sharadkumar Patel (Chairman & Managing Director), Dineshkumar Gelot (Whole-time Director), Vishalkumar Patel and Chetankumar Patel (Executive Directors), and three Independent Non-Executive Directors: Ms. Nidhiben Patel, Hetal Shah, and Heena Patel. They oversee the company's operations and strategic direction.

As of March 2023, the management team of Sotac Pharma includes the following individuals:<BR><BR>1. Sharadkumar Dashrathbhai Patel - Chairman & Managing Director<BR>2. Dineshkumar Babulal Gelot - Whole-time Director<BR>3. Vishalkumar Devrajbhai Patel - Executive Director<BR>4. Chetankumar Bachubhai Patel - Executive Director<BR>5. Ms. Nidhiben Patel - Independent Non-Executive Director<BR>6. Hetal Umangbhai Shah - Independent Non-Executive Director<BR>7. Heena Viral Patel - Independent Non-Executive Director<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

What does Sotac Pharma. do?

Sotac Pharmaceuticals Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of 252 Cr and a net profit of 14 Cr for June 2024. The company has a market cap of INR 143 Cr and a P/E ratio of 30.00.

Overview: <BR>Sotac Pharmaceuticals Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>Sotac Pharmaceuticals was originally formed as a Partnership Firm in 2015 and was converted to a Private Limited Company later that same year. The latest quarterly results reported net sales and profit for June 2024.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 252 Cr (Quarterly Results - Jun 2024) <BR>Most recent Net Profit: 14 Cr (Quarterly Results - Jun 2024) <BR>Market-cap value: INR 143 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 30.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.47 <BR>Return on Equity: 9.51% <BR>Price to Book: 3.17<BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the top shareholders of the Sotac Pharma.?

The top shareholders of Sotac Pharma include Kiran Baldevbhai Jotania with 13.11%, foreign institutional investors holding 15.12%, and Nav Capital Vcc - Nav Capital Emerging Star Fund as the largest public shareholder at 7.09%. Individual investors own 4.7% of the shares, with no pledged promoter holdings or mutual fund schemes.

The top shareholders of Sotac Pharma include several key players. The majority shareholders are the promoters, with Kiran Baldevbhai Jotania holding the highest stake at 13.11%. Additionally, there are three foreign institutional investors (FIIs) collectively holding 15.12% of the shares. The highest public shareholder is Nav Capital Vcc - Nav Capital Emerging Star Fund, which holds 7.09%. Individual investors account for 4.7% of the company's shares. Notably, there are no pledged promoter holdings or mutual fund schemes involved.

How big is Sotac Pharma.?

As of 24th July, Sotac Pharmaceuticals Ltd has a market capitalization of 137.00 Cr, with recent net sales of 104.11 Cr and a net profit of 4.64 Cr. Shareholder's funds are 45.26 Cr, and total assets amount to 103.90 Cr.

As of 24th July, Sotac Pharmaceuticals Ltd has a market capitalization of 137.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Sotac Pharmaceuticals reported Net Sales of 104.11 Cr and a Net Profit of 4.64 Cr.<BR><BR>The latest reporting period for the balance sheet is March 2024, with Shareholder's Funds amounting to 45.26 Cr and Total Assets of 103.90 Cr.

Is Sotac Pharma. overvalued or undervalued?

As of October 7, 2025, Sotac Pharma is fairly valued with a PE ratio of 26.26, an EV to EBITDA of 19.97, and a PEG ratio of 0.33, making it attractive compared to peers like Sun Pharma and Divi's Lab, despite a 13.16% decline over the past year.

As of 7 October 2025, the valuation grade for Sotac Pharma has moved from very attractive to attractive. The company is currently fairly valued. Key ratios include a PE ratio of 26.26, an EV to EBITDA of 19.97, and a PEG ratio of 0.33, indicating a relatively low growth expectation compared to its earnings. <BR><BR>In comparison to its peers, Sotac Pharma's PE ratio is lower than Sun Pharma's 34.6 and Divi's Lab's 70.24, which are considered expensive. However, it is higher than Cipla's attractive PE of 22.68 and Dr. Reddy's Labs at 18.37, both of which suggest a more favorable valuation. Despite a recent stock return of 5% over the past week compared to the Sensex's 2.02%, the longer-term performance shows a decline of 13.16% over the past year, reinforcing the notion that the stock is currently fairly valued within its sector.

How has been the historical performance of Sotac Pharma.?

Sotac Pharma's historical performance shows fluctuating net sales, peaking at 103.83 Cr in March 2024 before declining to 96.99 Cr in March 2025, while profitability improved significantly with profit after tax rising to 9.28 Cr in March 2025 from 3.58 Cr in the previous year. Total assets and liabilities both increased to 123.03 Cr in March 2025, indicating growth in operations despite negative cash flow from operating activities.

Answer:<BR>The historical performance of Sotac Pharma shows a fluctuating trend in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Sotac Pharma's net sales peaked at 103.83 Cr in March 2024 but declined to 96.99 Cr by March 2025, following a steady increase from 28.60 Cr in March 2020 to 77.48 Cr in March 2023. Total operating income mirrored this trend, reaching 96.99 Cr in March 2025. The company's total expenditure, excluding depreciation, was 83.34 Cr in March 2025, down from 95.32 Cr in March 2024, which contributed to an operating profit of 17.55 Cr in March 2025, a significant increase from 9.00 Cr in the previous year. Profit before tax also rose to 11.12 Cr in March 2025, compared to 3.96 Cr in March 2024, leading to a profit after tax of 9.28 Cr, up from 3.58 Cr. The earnings per share improved to 7.27 in March 2025 from 3.87 in March 2024. On the balance sheet, total assets increased to 123.03 Cr in March 2025, while total liabilities also rose to 123.03 Cr, indicating a growing scale of operations. Cash flow from operating activities remained negative at -4.00 Cr in March 2025, although cash flow from financing activities was positive at 16.00 Cr, reflecting ongoing investments and financing strategies.

Should I buy, sell or hold Sotac Pharmaceuticals Ltd?

Why is Sotac Pharmaceuticals Ltd falling/rising?

As of 04-Mar, Sotac Pharmaceuticals Ltd's stock price is stable at 111.00, but it has declined 6.33% over the past month and 9.83% year-to-date, raising concerns about its financial health and long-term growth potential. The stock's bearish trend and declining investor participation suggest a strong sell sentiment.

As of 04-Mar, Sotac Pharmaceuticals Ltd's stock price is currently stable at 111.00, showing no change (0.00%). However, the stock has experienced a decline in performance over the past month, with a decrease of 6.33%, and a year-to-date drop of 9.83%. Despite a positive return of 13.44% over the past year, the stock's recent performance has been overshadowed by weak long-term fundamentals. <BR><BR>The company has not declared results in the last six months, which raises concerns about its financial health. Additionally, the net sales growth rate of 11.90% over the past five years indicates poor long-term growth potential. The high Debt to EBITDA ratio of 2.56 times further suggests a low ability to service debt, contributing to the stock's perception as a strong sell.<BR><BR>Moreover, the stock is trading below its moving averages across various time frames, indicating a bearish trend. Investor participation has also declined, with delivery volume falling by 28.57% against the five-day average, which may reflect reduced confidence among investors. Overall, these factors contribute to the stock's current stagnation and potential for further decline.

Which are the latest news on Sotac Pharma.?